SAN MATEO, Calif.--(BUSINESS WIRE)--Bayhill Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging its proprietary BHT-DNA™ platform to develop novel and targeted autoimmune disease treatments, announced today that Mark W. Schwartz, Ph.D., CEO and President, is scheduled to speak at Bio-Europe Spring® 2009, to be held at the Milano Convention Centre (MIC) in Milan, Italy from March 16-18, 2009.
